{"id":"NCT03280264","sponsor":"Kyowa Kirin Co., Ltd.","briefTitle":"Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism","officialTitle":"An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Who Are Unable to Undergo Parathyroidectomy or Relapse After Parathyroidectomy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-30","primaryCompletion":"2019-04-09","completion":"2019-04-09","firstPosted":"2017-09-12","resultsPosted":"2021-05-27","lastUpdate":"2021-05-27"},"enrollment":18,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parathyroid Carcinoma","Primary Hyperparathyroidism"],"interventions":[{"type":"DRUG","name":"KHK7580","otherNames":["evocalcet"]}],"arms":[{"label":"KHK7580","type":"EXPERIMENTAL"}],"summary":"To evaluate the efficacy of KHK7580 orally administered up to 24 weeks for hypercalcemia in patient with parathyroid carcinoma or primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy.","primaryOutcome":{"measure":"The Number and Percentage of Patients Who Achived a Serum Corrected Ca Concentration of Under 10.3 mg/dL for at Least 2weeks During Titration Phase.","timeFrame":"Up to 24 weeks","effectByArm":[{"arm":"KHK7580 (2-24 mg)","deltaMin":14,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":18},"commonTop":["Nasopharyngitis","Nausea","Chest pain","Cystitis","Influenza"]}}